Literature DB >> 12215898

Polymorphisms of human CD19 gene: possible association with susceptibility to systemic lupus erythematosus in Japanese.

K Kuroki1, N Tsuchiya, B P Tsao, J M Grossman, T Fukazawa, K Hagiwara, H Kano, M Takazoe, T Iwata, H Hashimoto, K Tokunaga.   

Abstract

CD19 regulates the signaling for B lymphocyte development, activation and proliferation. In mice, CD19 deficiency and overexpression were shown to result in hypogammaglobulinemia and autoantibody production, respectively. In the present study, we screened for the polymorphisms of CD19, and examined the detected polymorphisms for the association with rheumatoid arthritis (RA), Crohn's disease and systemic lupus erythematosus (SLE). Two SNPs, c.705G>T (P235P and IVS14-30C>T, were decreased (P = 0.0096 and P = 0.028, respectively), in SLE. A GT repeat polymorphism, c.*132(GT)(12-18), was detected within the 3'-untranslated region, and individuals with > or =15 times repeat was significantly increased in the independent two groups of Japanese SLE patients (P = 0.011 and P = 0.035, respectively); the overall difference between total SLE and controls was striking (P = 0.0061). No association was observed for RA and Crohn's disease. In addition, no variations other than the common polymorphisms were detected in four patients with common variable immunodeficiency, the phenotype of which resembles CD19 deficient mice. In Caucasian SLE families, this GT repeat polymorphism was rare. CD19 mRNA level in the isolated peripheral blood B lymphocytes was lower in individuals possessing (GT)(15-18) alleles compared with those without these alleles, both in controls and in SLE patients; however, the difference did not reach statistical significance. These results suggested that either the slight reduction in the CD19 mRNA level associated with the elongation of GT repeat, or an allele of another locus in linkage disequilibrium with CD19 (GT)(15-18), may be associated with susceptibility to SLE in Japanese.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215898     DOI: 10.1038/sj.gene.6363906

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  6 in total

Review 1.  3' end mRNA processing: molecular mechanisms and implications for health and disease.

Authors:  Sven Danckwardt; Matthias W Hentze; Andreas E Kulozik
Journal:  EMBO J       Date:  2008-02-06       Impact factor: 11.598

2.  Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss.

Authors:  Donna A Culton; Matilda W Nicholas; Donna O Bunch; Quan Li Zhen; Thomas B Kepler; Mary Anne Dooley; Chandra Mohan; Patrick H Nachman; Stephen H Clarke
Journal:  J Clin Immunol       Date:  2006-12-29       Impact factor: 8.317

3.  The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans.

Authors:  Laurence Menard; David Saadoun; Isabelle Isnardi; Yen-Shing Ng; Greta Meyers; Christopher Massad; Christina Price; Clara Abraham; Roja Motaghedi; Jane H Buckner; Peter K Gregersen; Eric Meffre
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

4.  Agammaglobulinemia associated with BCR⁻ B cells and enhanced expression of CD19.

Authors:  A Kerry Dobbs; Amma Bosompem; Elaine Coustan-Smith; Gayle Tyerman; Frank T Saulsbury; Mary Ellen Conley
Journal:  Blood       Date:  2011-06-21       Impact factor: 22.113

5.  Cloning and Expression of CD19, a Human B-Cell Marker in NIH-3T3 Cell Line.

Authors:  Hajar Abbasi-Kenarsari; Farzaneh Shafaghat; Behzad Baradaran; Ali Akbar Movassaghpour; Dariush Shanehbandi; Tohid Kazemi
Journal:  Avicenna J Med Biotechnol       Date:  2015 Jan-Mar

Review 6.  Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity.

Authors:  Taher E Taher; Jonas Bystrom; Voon H Ong; David A Isenberg; Yves Renaudineau; David J Abraham; Rizgar A Mageed
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.